Skip to main content
Figure 3 | Retrovirology

Figure 3

From: Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq

Figure 3

Characterization of the drug resistance mutations identified in the ALIVE cohort after treatment failure. (A) The frequency of different types of HIV drug resistance mutations found in 26 patient samples with after treatment failure. Major mutations are as defined by the Stanford drug resistance database and accessory mutations are all other mutations associated with drug resistance as designated by the International AIDS Society (IAS). (B) Percentages of the 29 emerging mutations found at the second time point but not first time for all participant samples that were major or accessory mutations and whether the mutations rose above the 20% threshold expected to be detected by commercial HIV drug resistance genotyping techniques.

Back to article page

Retrovirology

ISSN: 1742-4690

Contact us